Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
05
08
2019
accepted:
06
04
2020
revised:
28
02
2020
pubmed:
13
5
2020
medline:
20
2
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancers. We sought to estimate the prevalence of cancer-related distress and to identify predictors of distress in an international sample of unaffected women with a BRCA mutation. Women with a BRCA1/2 mutation and no previous cancer diagnosis were recruited from the United States, Canada, the United Kingdom, Australia and from a national advocacy group. Using an online survey, we asked about cancer risk reduction options and screening, and we measured cancer-related distress using the Impact of Event Scale. Among 576 respondents, mean age was 40.8 years (SD = 8.1). On average 4.9 years after a positive test result, 16.3% of women reported moderate-to-severe cancer-related distress. Women who had undergone risk-reducing breast and ovarian surgery were less likely to have (moderate or severe) cancer-related distress compared to other women (22.0% versus 11.4%, P value = 0.007). Women recruited from the advocacy group were more likely to have cancer-related distress than other women (21.6% versus 5.3%, P value = 0.002). Approximately 16% of women with a BRCA1 or BRCA2 mutation experience distress levels comparable to those of women after a cancer diagnosis. Distress was lower for women who had risk-reducing surgery.
Sections du résumé
BACKGROUND
Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancers. We sought to estimate the prevalence of cancer-related distress and to identify predictors of distress in an international sample of unaffected women with a BRCA mutation.
METHODS
Women with a BRCA1/2 mutation and no previous cancer diagnosis were recruited from the United States, Canada, the United Kingdom, Australia and from a national advocacy group. Using an online survey, we asked about cancer risk reduction options and screening, and we measured cancer-related distress using the Impact of Event Scale.
RESULTS
Among 576 respondents, mean age was 40.8 years (SD = 8.1). On average 4.9 years after a positive test result, 16.3% of women reported moderate-to-severe cancer-related distress. Women who had undergone risk-reducing breast and ovarian surgery were less likely to have (moderate or severe) cancer-related distress compared to other women (22.0% versus 11.4%, P value = 0.007). Women recruited from the advocacy group were more likely to have cancer-related distress than other women (21.6% versus 5.3%, P value = 0.002).
CONCLUSIONS
Approximately 16% of women with a BRCA1 or BRCA2 mutation experience distress levels comparable to those of women after a cancer diagnosis. Distress was lower for women who had risk-reducing surgery.
Identifiants
pubmed: 32393849
doi: 10.1038/s41416-020-0861-3
pii: 10.1038/s41416-020-0861-3
pmc: PMC7374749
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-274Références
Bosch, N., Junyent, N., Gadea, N., Brunet, J., Ramón y Cajal, T., Torres, A. et al. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? Breast 21, 755–760 (2012).
doi: 10.1016/j.breast.2012.02.004
Graves, K. D., Vegella, P., Poggi, E. A., Peshkin, B. N., Tong, A., Isaacs, C. et al. Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol. Biomark. Prev. 21, 445–455 (2012).
doi: 10.1158/1055-9965.EPI-11-0991
Halbert, C. H., Stopfer, J. E., McDonald, J., Weathers, B., Collier, A., Troxel, A. B. et al. Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women’s concerns? J. Clin. Oncol. 29, 4302–4306 (2011).
doi: 10.1200/JCO.2010.33.1561
Smith, A. W., Dougall, A. L., Posluszny, D. M., Somers, T. J., Rubinstein, W. S. & Baum, A. Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 17, 767–773 (2008).
doi: 10.1002/pon.1291
Beran, T. M., Stanton, A. L., Kwan, L., Seldon, J., Bower, J. E., Vodermaier, A. et al. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal? Ann. Behav. Med. 36, 107–116 (2008).
doi: 10.1007/s12160-008-9060-9
Schwartz, M. D., Peshkin, B. N., Hughes, C., Main, D., Isaacs, C. & Lerman, C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J. Clin. Oncol. 20, 514–520 (2002).
doi: 10.1200/JCO.2002.20.2.514
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
doi: 10.1001/jama.2017.7112
King, M. C., Levy-Lahad, E. & Lahad, A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312, 1091–1092 (2014).
doi: 10.1001/jama.2014.12483
Bridges, J. F., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A. et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14, 403–413 (2011).
doi: 10.1016/j.jval.2010.11.013
Liede, A., Mansfield, C. A., Metcalfe, K. A., Price, M. A., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder, C. et al. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res. Treat. 165, 433–444 (2017).
doi: 10.1007/s10549-017-4332-3
Horowitz, M., Wilner, N. & Alvarez, W. Impact of Event Scale: a measure of subjective stress. Psychosom. Med. 41, 209–218 (1979).
doi: 10.1097/00006842-197905000-00004
Graves, K. D., Wenzel, L., Schwartz, M. D., Luta, G., Wileyto, P., Narod, S. et al. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomark. Prev. 19, 648–654 (2010).
doi: 10.1158/1055-9965.EPI-09-0548
Ringwald, J., Wochnowski, C., Bosse, K., Giel, K. E., Schäffeler, N., Zipfel, S. et al. Psychological distress, anxiety, and depression of cancer-affected BRCA1/2 mutation carriers: a systematic review. J. Genet. Couns. 25, 880–891 (2016).
doi: 10.1007/s10897-016-9949-6
Metcalfe, K. A., Mian, N., Enmore, M., Poll, A., Llacuachaqui, M., Nanda, S. et al. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res. Treat. 133, 735–740 (2012).
doi: 10.1007/s10549-011-1941-0
Thewes, B., Meiser, B. & Hickie, I. B. Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology 10, 459–468 (2001).
doi: 10.1002/pon.533